Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access October 7, 2010

EMMPRIN and fascin expression in non-small cell lung carcinoma

Mehmet Kefeli, Aysen Taslak Sengul, Levent Yildiz, Sancar Baris, Ahmet Basoglu and Bedri Kandemir
From the journal Open Medicine

Abstract

Fascin and EMMPRIN (CD 147) have a demonstrated relationship with the invasion and progression of many tumors. The aim of this study was to analyze fascin and EMMPRIN expression in non-small cell lung carcinoma and their relationship with clinicopathologic features. Fascin and EMMPRIN expression levels were investigated via the immunohistochemistry of paraffin-embedded tissues of 64 patients with non-small cell lung carcinoma, including 46 squamous cell carcinoma and 18 adenocarcinoma patients. The patients were scored on the basis of staining extent and intensity, and were then assigned a combined score. Fascin expression was present in 44 of 46 (95.6%) patients with SCC and 16 of 18 (88.8%) patients with adenocarcinoma. There was a significant correlation between fascin expression and tumor stage in the SCC and adenocarcinoma groups. EMMPRIN expression was observed in all patients with SCC (46 of 46, 100%) and 16 of 18 (88.8%) patients with adenocarcinoma. There was significant correlation between EMMPRIN expression and both tumor stage and diameter in the SCC group, but not in the adenocarcinoma group. This study revealed that high levels of fascin and EMMPRIN expression may indicate the importance of their roles in the progression of non-small cell lung carcinoma and they could be used as prognostic marker for these tumors.

[1] Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J., Cancer statistics, CA Cancer J. Clin., 2008, 58, 71–96 http://dx.doi.org/10.3322/CA.2007.001010.3322/CA.2007.0010Search in Google Scholar

[2] Husain A.N., The Lung, In: Kumar V., Abbas A.K., Fausto N., Aster J.C. eds. Robbins and Cotran Pathologic Basis of Disease. Eighth Edition, Philadelphia, Saunders Elsevier, 2010, 677–737 10.1016/B978-1-4377-0792-2.50020-1Search in Google Scholar

[3] Bepler G., Goodridge Carney D., Djulbegovic B., Clark R.A., Tockman M., A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest, Cancer Control 2003, 10, 306–14 10.1177/107327480301000405Search in Google Scholar

[4] Al-Saad S., Al-Shibli K., Donnem T., Persson M., Bremnes R.M., Busund L.T., The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer, Br. J. Cancer, 2008, 99, 1476–83 http://dx.doi.org/10.1038/sj.bjc.660471310.1038/sj.bjc.6604713Search in Google Scholar

[5] Nakashima M., Ohike N., Nagasaki K., Adachi M., Morohoshi T., Prognostic significance of the maspin tumor suppressor gene in pulmonary adenocarcinoma, J. Cancer Res. Clin. Oncol., 2004, 130, 475–9 http://dx.doi.org/10.1007/s00432-004-0571-x10.1007/s00432-004-0571-xSearch in Google Scholar

[6] Perner S., Wagner P.L., Soltermann A., LaFargue C., Tischler V., Weir B.A., Weder W., Meyerson M., Giordano T.J., Moch H., Rubin M.A., TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival, J. Pathol., 2009, 217, 65–72 http://dx.doi.org/10.1002/path.244310.1002/path.2443Search in Google Scholar

[7] Pelosi G., Barisella M., Pasini F., Leon M.E., Veronesi G., Spaggiari L., Fraggetta F., Iannucci A., Masullo M., Sonzogni A., Maffini F., Viale G., CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients, Mod. Pathol., 2004, 17, 711–21 http://dx.doi.org/10.1038/modpathol.380011010.1038/modpathol.3800110Search in Google Scholar

[8] Hirabayashi H., Ohta M., Tanaka H., Sakaguchi M., Fujii Y., Miyoshi S., Matsuda H., Prognostic significance of p27KIP1 expression in resected non-small cell lung cancers: analysis in combination with expressions of p16INK4A, pRB, and p53, J. Surg. Oncol., 2002, 81, 177–84 http://dx.doi.org/10.1002/jso.1017610.1002/jso.10176Search in Google Scholar

[9] Sun J., Hemler M.E., Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions, Cancer Res., 2001, 61, 2276–81 Search in Google Scholar

[10] Muramatsu T., Miyauchi T., Basigin (CD147): a multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion, Histol. Histopathol, 2003, 18, 981–7 Search in Google Scholar

[11] Shapiro S.D., Matrix metalloproteinase degradation of extracellular matrix: biological consequences, Curr. Opin. Cell Biol., 1998, 10, 602–8 http://dx.doi.org/10.1016/S0955-0674(98)80035-510.1016/S0955-0674(98)80035-5Search in Google Scholar

[12] Chambers A.F., Matrisian L.M., Changing views of the role of matrix metalloproteinases in metastasis, J. Natl. Cancer Inst., 1997, 89, 1260–70 http://dx.doi.org/10.1093/jnci/89.17.126010.1093/jnci/89.17.1260Search in Google Scholar PubMed

[13] Riethdorf S., Reimers N., Assmann V., Kornfeld J.W., Terracciano L., Sauter G., Pantel K., High incidence of EMMPRIN expression in human tumors, Int. J. Cancer 2006, 119, 1800–10 http://dx.doi.org/10.1002/ijc.2206210.1002/ijc.22062Search in Google Scholar PubMed

[14] Tsai W.C., Chao Y.C., Sheu L.F., Lin Y.F., Nieh S., Chen A., Yu C.P., Jin J.S., EMMPRIN and fascin overexpression associated with clinicopathologic parameters of pancreatobiliary adenocarcinoma in Chinese people, APMIS, 2007, 115, 929–38 http://dx.doi.org/10.1111/j.1600-0463.2007.apm_858.x10.1111/j.1600-0463.2007.apm_858.xSearch in Google Scholar PubMed

[15] Zheng H.C., Takahashi H., Murai Y., Cui Z.G., Nomoto K., Miwa S., Tsuneyama K., Takano Y., Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis, Br. J. Cancer, 2006, 95, 1371–8 http://dx.doi.org/10.1038/sj.bjc.660342510.1038/sj.bjc.6603425Search in Google Scholar PubMed PubMed Central

[16] Tsai W.C., Chao Y.C., Lee W.H., Chen A., Sheu L.F., Jin J.S., Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters, Histopathology, 2006, 49, 388–95 http://dx.doi.org/10.1111/j.1365-2559.2006.02516.x10.1111/j.1365-2559.2006.02516.xSearch in Google Scholar PubMed

[17] Han Z.D., He H.C., Bi X.C., Qin W.J., Dai Q.S., Zou J., Ye Y.K., Liang Y.X., Zeng G.H., Zhu G., Chen Z.N., Zhong W.D., Expression and clinical significance of CD147 in genitourinary carcinomas, J. Surg. Res., 2008, (In press) Search in Google Scholar

[18] De Arcangelis A., Georges-Labouesse E., Adams J.C., Expression of fascin-1, the gene encoding the actin-bundling protein fascin-1, during mouse embryogenesis, Gene Exp. Patt., 2004, 4, 637–43 http://dx.doi.org/10.1016/j.modgep.2004.04.01210.1016/j.modgep.2004.04.012Search in Google Scholar PubMed

[19] Hashimoto Y., Skacel M., Adams J.C., Roles of fascin in human carcinoma motility and signaling: Prospects for a novel biomarker?, Int. J. Biochem. Cell Biol., 2005, 37, 1787–804 http://dx.doi.org/10.1016/j.biocel.2005.05.00410.1016/j.biocel.2005.05.004Search in Google Scholar PubMed

[20] Kureishy N., Sapountzi V., Prag S., et al, Fascins, and their roles in cell structure and function, Bioessays, 2002, 24, 350–61 http://dx.doi.org/10.1002/bies.1007010.1002/bies.10070Search in Google Scholar PubMed

[21] Pelosi G., Pastorino U., Pasini F., et al, Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer, Br. J. Cancer, 2003, 88, 537–47 http://dx.doi.org/10.1038/sj.bjc.660073110.1038/sj.bjc.6600731Search in Google Scholar PubMed PubMed Central

[22] Peraud A., Mondal S., Hawkins C., et al, Expression of fascin, an actin-bundling protein, in astrocytomas of varying grades, Brain Tumor Pathol., 2003, 20, 53–8 http://dx.doi.org/10.1007/BF0248344710.1007/BF02483447Search in Google Scholar PubMed

[23] Rodriguez-Pinilla S.M., Sarrio D., Honrado E., et al, Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin. Cancer Res, 2006, 12, 1533–39 http://dx.doi.org/10.1158/1078-0432.CCR-05-228110.1158/1078-0432.CCR-05-2281Search in Google Scholar PubMed

[24] Tong G.X., Yee H., Chiriboga L., et al, Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder, Hum. Pathol., 2005, 36, 741–6 http://dx.doi.org/10.1016/j.humpath.2005.05.00510.1016/j.humpath.2005.05.005Search in Google Scholar PubMed

[25] Grothey A., Hashizume R., Sahin A.A., et al, Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer, Br. J. Cancer, 2000, 83, 870–73 http://dx.doi.org/10.1054/bjoc.2000.139510.1054/bjoc.2000.1395Search in Google Scholar PubMed PubMed Central

[26] Hashimoto Y., Shimada Y., Kawamura J., et al, The prognostic relevance of fascin expression in human gastric carcinoma, Oncology, 2004, 67, 262–70 http://dx.doi.org/10.1159/00008132710.1159/000081327Search in Google Scholar PubMed

[27] Pelosi G., Pastorino U., Pasini F., Maissoneuve P., Fraggetta F., Iannucci A., Sonzogni A., De Manzoni G., Terzi A., Durante E., Bresaola E., Pezzella F., Viale G., Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer, Br. J. Cancer, 2003, 88, 537–47 http://dx.doi.org/10.1038/sj.bjc.660073110.1038/sj.bjc.6600731Search in Google Scholar PubMed PubMed Central

[28] Choi P.J., Yang D.K., Son C.H., Lee K.E., Lee J.I., Roh M.S., Fascin immunoreactivity for preoperatively predicting lymph node metastases in peripheral adenocarcinoma of the lung 3 cm or less in diameter, Eur. J. Cardiothorac Surg, 2006, 30, 538–42 http://dx.doi.org/10.1016/j.ejcts.2006.06.02910.1016/j.ejcts.2006.06.029Search in Google Scholar PubMed

[29] Hakuma N., Betsuyaku T., Kinoshita I., Itoh T., Kaga K., Kondo S., Nishimura M., Dosaka-Akita H., High incidence of extracellular matrix metalloproteinase inducer expression in non-small cell lung cancers. Association with clinicopathological parameters, Oncology, 2007, 72, 197–204 http://dx.doi.org/10.1159/00011282610.1159/000112826Search in Google Scholar PubMed

[30] Sienel W., Polzer B., Elshawi K., Lindner M., Morresi-Hauf A., Vay C., Eder F., Passlick B., Klein CA., Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9, Mod. Pathol., 2008, 21, 1130–8 http://dx.doi.org/10.1038/modpathol.2008.10210.1038/modpathol.2008.102Search in Google Scholar PubMed

[31] Travis W.D., Brambilla E., Muller-Hermelink K.H., Harris C.C., Pathology and genetics of tumours of the lung, pleura, thymus and heart, IARC Press, Lyon 2004, p. 9–124 Search in Google Scholar

Published Online: 2010-10-7
Published in Print: 2010-12-1

© 2010 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Scroll Up Arrow